Novo Nordisk markets the diabetes drug under the brand name Ozempic. Medical professionals administer both drugs via injection. Recently, various companies succeeded in having two Novo Nordisk patents relating to oral semaglutide administration revoked. Novo Nordisk markets the oral medication for type 2 diabetes under the trade name Rybelsus.